Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

This study has been completed.
Information provided by (Responsible Party):
Syntrix Biosystems, Inc. Identifier:
First received: July 8, 2009
Last updated: November 1, 2012
Last verified: November 2012

The purpose of this study is to compare the safety and pharmacokinetic properties (the absorption, distribution and excretion) of two preparations of aminopterin (0.25 mg tablets and 1.0 mg tablets) following oral administration by subjects with moderate to severe psoriasis.

Condition Intervention Phase
Drug: Aminopterin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase 1 Study Comparing The Safety and Oral Pharmacokinetics Of 0.25 mg and 1.0 mg Aminopterin Tablets In Human Subjects With Psoriasis

Resource links provided by NLM:

Further study details as provided by Syntrix Biosystems, Inc.:

Primary Outcome Measures:
  • Aminopterin area under the curve [ Time Frame: 0.0, 0.5, 1.0, 1.5, 2.0, 3.0, 5.0, 7.0, 10.0 and 12.0 hours ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Aminopterin concentration maximum, time to maximal aminopterin concentration, aminopterin volume of distribution and aminopterin half-life. [ Time Frame: 0.0, 0.5, 1.0, 1.5, 2.0, 3.0, 5.0, 7.0, 10.0 and 12.0 hours ] [ Designated as safety issue: No ]

Enrollment: 22
Study Start Date: June 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Aminopterin one 1.0 mg tablet Drug: Aminopterin
oral tablets, 1.0 mg dose, once weekly, two weeks
Active Comparator: Aminopterin 1 four 0.25 mg tablets Drug: Aminopterin
oral tablets, 1.0 mg dose, once weekly, two weeks


Ages Eligible for Study:   21 Years to 59 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Give written informed consent by signing an IRB-approved Informed Consent.
  • Be under treatment for at least moderate to severe psoriasis (diagnosis confirmed by a dermatologist) with MTX (10-20 mg per week) for a minimum of 3 months. Moderate to severe psoriasis is defined here as plaque-type psoriasis affecting a body surface area > 10%.
  • Be 21 years of age or older, but not 60 years of age or older.
  • If participant is female of child bearing potential, then subject must indicate that she is not pregnant.
  • Must be fully informed of the potential for AMT to adversely affect a fetus, and must agree to use highly effective method of birth control beginning at the time of consent, during the study, and for 3 months after leaving the study.
  • Women of childbearing potential may enter the study only after a confirmed menstrual period, and must have a negative urine pregnancy test at the time of screening and within 24 hours of each study drug dose.
  • Have adequate hematologic function as evidenced by the following :results obtained from a blood sample drawn within 2 days of day 0:

    • WBC > 4,500/ mm3
    • Platelet Count > 150,000/mm3
    • Hemoglobin > 12.0 gm/dL
  • Have adequate liver function as evidenced by the following results obtained from a blood sample drawn within 2 days of day 0:

    • AST (SGOT) ≤ 40 IU/L
    • ALT (SGPT) ≤ 40 IU/L
    • Alkaline Phosphatase ≤ 120 IU/L
    • Total Bilirubin ≤ 1.2 mg/dL
  • Have adequate renal function as evidenced by the following result obtained from a blood sample drawn within 2 days of day 0:

    • GFR estimated by Cockcroft-Gault formula:
    • > 90 ml/min (male)
    • > 90 ml/min (female)
  • Have no detectable urine glucose, urine ketones, or urine protein from a sample obtained within 2 days of day 0.
  • Weight of 35 to 90 kg.

Exclusion Criteria:

  • A known history of hepatitis, liver fibrosis or cirrhosis (grades IIIA, IIIB or IV), diabetes (type I or II), HIV infection, tuberculosis, interstitial lung disease, or an abnormal screening chest x-ray that is consistent with interstitial lung disease.
  • Known peptic ulcer, ulcerative colitis or Crohn's disease.
  • Body mass index (BMI) <19.0 or > 35.0 (see appendix C).
  • Within 2 weeks prior to randomization use of any of the following medications that may result in drug/drug interactions with aminopterin: methotrexate, trimethoprim with or without sulfamethoxazole; sulfonamides; sulfonylureas; pyrimethamine; triamethamine; dipyridamole; colchicine; probenecid; aminoglycosides; theophylline; phenytoin; and folinic acid (i.e., leucovorin) unless prescribed by the investigator to treat study drug related toxicity.
  • Within 2 weeks prior to randomization use of salicylates, non-steroidal anti-inflammatory (NSAID) drugs, including Over-The-Counter nonprescription use of aspirin, ibuprofen or naproxen.
  • Use of medications that may be negatively influenced by regular folic acid supplementation such as the anti-epileptics phenobarbital, diphenylhydantoin, and primidone.
  • Use of any investigational medication within 30 days prior to admission to the study.
  • Inability to abstain from alcohol during the study.
  • A history of substance abuse, drug addiction or alcoholism.
  • Unwillingness to use an adequate form of contraception during the study and for 3 months after the study.
  • A female who is pregnant, intends to become pregnant during the study (or within 6 months after study completion), or nursing.
  • Concurrent participation in another clinical trial involving experimental treatment.
  • Current and uncontrolled infection, cardiovascular, pulmonary, hepatic or GI conditions that will interfere with the conduct of the trial or pose an additional morbid risk.
  • Any renal conditions that will interfere with the conduct of the trial or pose an additional morbid risk.
  • Any concurrent disease or condition that in the opinion of the investigator impairs the subject's ability to complete the trial. Psychological, familial, sociological, geographical or medical conditions which, in the Investigator's opinion, could compromise compliance with the objectives and procedures of this protocol or obscure interpretation of the trial's data.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00937027

United States, Texas
Baylor Research Institute
Dallas, Texas, United States, 75246
Sponsors and Collaborators
Syntrix Biosystems, Inc.
Principal Investigator: Alan Menter, M.D. Baylor Research Institute
  More Information

No publications provided by Syntrix Biosystems, Inc.

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Syntrix Biosystems, Inc. Identifier: NCT00937027     History of Changes
Other Study ID Numbers: Syntrix-AMT-PSO-101, NIH Grant #: R43AI068282
Study First Received: July 8, 2009
Last Updated: November 1, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Syntrix Biosystems, Inc.:
Antiinflammatory drug
Autoimmune disease

Additional relevant MeSH terms:
Skin Diseases
Skin Diseases, Papulosquamous
Enzyme Inhibitors
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on August 27, 2015